Russia rejects Abbott Laboratories' plan to buy Petrovax
MOSCOW, April 19
MOSCOW, April 19 (Reuters) - Russia's government commission on foreign investment has rejected U.S. Abbott Laboratories' plan to buy Russian pharmaceutical producer Petrovax, the head of the Russian antitrust regulator said on Friday.
"The commission has reviewed the question about the sale to U.S. company Abbott of Petrovax Pharm. As a result of very lengthy discussion the U.S. company was denied to make this deal," Igor Artemyev, head of the Federal Anti-Monopoly Service (FAS), told reporters.
Abbott Laboratories filed for permission to buy the Russian vaccine developer and producer last year.
Abbott Laboratories spokeswoman Irina Gushchina said the company had not received any official information regarding the state of its application.
- Housing, jobs data weaken, but overall economic picture still upbeat
- Putin critic Khodorkovsky free after pardon, heads for Germany |
- Target cyber breach hits 40 million payment cards at holiday peak |
- Pizza outlet attacked as India, U.S. fail to cool diplomat row |
- New York Mayor-elect's reputation for lateness parodied on Twitter